The ligand paradox between affinity and efficacy: can you be there and not make a difference?

被引:108
作者
Kenakin, T
Onaran, O
机构
[1] GlaxoSmithKline Res & Dev Ltd, 7TM Pharmacol Syst Res, Res Triangle Pk, NC 27709 USA
[2] Ankara Univ, Fac Med, Dept Pharmacol, Ankara, Turkey
关键词
D O I
10.1016/S0165-6147(02)02036-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Efficacy is described in terms of the ligand-induced bias of receptor microconformations. A virtual simulation of binding of a collection of random ligands can reconcile an apparent paradox in receptor theory, namely the theoretical requirement that affinity and efficacy be related to each other and the experimental fact that medicinal chemistry often can separate structure-activity relationships for affinity and efficacy. The simulation indicates that homoscedacity in the relationship allows for a general correlation with isolated instances of non-compliance. This leads to the conclusion that if a ligand binds to the receptor it will change the receptor by its presence. Therefore, this suggests that all ligands with macro-affinity should be extensively studied for pharmacological activities other than simple G-protein activation with the potential promise of discovering new therapeutic applications for old drugs.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 62 条
[1]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[2]   ESSENTIAL DYNAMICS OF PROTEINS [J].
AMADEI, A ;
LINSSEN, ABM ;
BERENDSEN, HJC .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1993, 17 (04) :412-425
[3]   HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication [J].
Amara, A ;
LeGall, S ;
Schwartz, O ;
Salamero, J ;
Montes, M ;
Loetscher, P ;
Baggiolini, M ;
Virelizier, JL ;
ArenzanaSeisdedos, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :139-146
[4]  
ARIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32
[5]   PRIMARY STRUCTURE EFFECTS ON PEPTIDE GROUP HYDROGEN-EXCHANGE [J].
BAI, YW ;
MILNE, JS ;
MAYNE, L ;
ENGLANDER, SW .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1993, 17 (01) :75-86
[6]   PROTEIN-FOLDING INTERMEDIATES - NATIVE-STATE HYDROGEN-EXCHANGE [J].
BAI, YW ;
SOSNICK, TR ;
MAYNE, L ;
ENGLANDER, SW .
SCIENCE, 1995, 269 (5221) :192-197
[7]  
BENOVIC JL, 1988, J BIOL CHEM, V263, P3893
[8]  
Berg KA, 1999, MOL PHARMACOL, V55, P863
[9]  
Black J, 1996, ANNU REV PHARMACOL, V36, P1
[10]   Differential opioid agonist regulation of the mouse mu opioid receptor [J].
Blake, AD ;
Bot, G ;
Freeman, JC ;
Reisine, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (02) :782-790